Abstract:Bestatin, a small molecular weight dipeptide, is a potent inhibitor of various aminopeptidases as well as LTA4 hydrolase. Various physiological functions of Bestatin have been identified, viz.: (1) an immunomodifier for enhancing the proliferation of normal human bone marrow granulocyte-macrophage progenitor cells to form CFU-GM colonies; Bestatin exerts a direct stimulating effect on lymphocytes via its fixation on the cell surface and an indirect effect on monocytes via aminopeptidase B inhibition of tuftsin catabolism; (2) an immunorestorator and curative or preventive agent for spontaneous tumor; Bestatin alone or its combination with chemicals can prolongate the disease-free interval and survival period in adult acute or chronic leukemia, therefore, it was primarily marketed in 1987 in Japan as an anticancer drug and servers as the only marketed inhibitor of Aminopeptidase N (APN/CD13) to cure leukemia to date; (3) a pan-hematopoietic stimulator and restorator; Bestatin promotes granulocytopoiesis and thrombocytopoiesis in vitro and restores them in myelo-hypoplastic men; (4) an inhibitor of several natural opioid peptides. Based on the knowledge that APN can cleave several bioactive neuropeptides such as Met-enkaphalins, Leu-enkaphalins, beta-Endorphin, and so on, the anti-aminopeptidase action of Bestatin also allows it to protect endopeptides against their catabolism, exhibiting analgesic activity. Although many scientific studies and great accomplishments have been achieved in this field, a large amount of problems are unsolved. This article reviews the promising results obtained for future development of the analgesic activity of Bestatin that can be of vital interest in a number of severe and chronic pain syndromes.

The Synthesis and Activity Evaluation of a Bestatin Derivative (LYP) As an Aminopeptidase N Inhibitor

Synthesis and Activity Evaluation of a New Bestatin Derivative LYP2 As an Aminopeptidase N Inhibitor.

LYP3, a new bestatin derivative for aminopeptidase N inhibition.

The Review of the Synthesis of Bestatin, an Effective Inhibitor of Aminopeptidase N

Design, synthesis and biological evaluation of novel L-isoserine tripeptide derivatives as aminopeptidase N inhibitors.

Design, Synthesis and Biological Evaluation of Novel Amino Acid Ureido Derivatives As Aminopeptidase N/CD13 Inhibitors

Design, Synthesis and Biological Evaluation of New Pyrazoline-Based Hydroxamic Acid Derivatives as Aminopeptidase N (APN) Inhibitors.

Design, synthesis and biological evaluation of novel L-lysine ureido derivatives as aminopeptidase N inhibitors.

Design, synthesis and preliminary activity evaluation of novel 3-amino-2-hydroxyl-3-phenylpropanoic acid derivatives as aminopeptidase N/CD13 inhibitors.

Design,synthesis and Bioactivity Evalution of N-substituted-2,6-dioxopiperidin Derivatives As Aminopeptidase N(APN/CD13) Inhibitors

Progress in the development of bestatin analogues as aminopeptidases inhibitors.

Synthesis of a Novel Series of L-isoserine Derivatives As Aminopeptidase N Inhibitors

Design, Synthesis and Preliminary Activity Evaluation of Novel L-Lysine Derivatives As Aminopeptidase N/Cd13 Inhibitors

The Synthesis and Preliminary Activity Assay in Vitro of Peptide-Like Derivatives As APN Inhibitors

Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent.

Design, Synthesis And Activity Study Of Aminopeptidase N Targeted 3-Amino-2-Hydroxy-4-Phenyl-Butanoic Acid Derivatives

The Analgesic Activity Of Bestatin As A Potent Apn Inhibitor

The Effect of Different Species Aminopeptidase N Structure on the Activity Screening of Aminopeptidase N Inhibitor

Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.

A Novel Aminopeptidase N Inhibitor Developed by Virtual Screening Approach

Design, Synthesis, and Preliminary Studies of the Activity of Novel Derivatives of N-cinnamoyl-l-aspartic Acid As Inhibitors of Aminopeptidase N/CD13